In8Bio, Inc.INAB

IN8BIO, INC. is a pre-revenue biotechnology company chasing a future where high-dose chemotherapy and immunotherapy can be delivered in one stroke, a pitch that sounds like a one-stop oncology platform. The company’s public pages promise technology that “uniquely allows us to simultaneously combine high-dose chemotherapy with immunotherapy,” but the filings admit there is no revenue yet and that any failure in preclinical or clinical development could add costs or block future sales. The firm’s trademark filings and service marks read like a branding agency’s trophy case, not a product launch pipeline.

The latest 10-Q for the quarter ended 31 March 2026 shows a net loss of $5.1 million, operating loss of $5.1 million, and cash used in operations of $4.9 million. Assets total $26.3 million against liabilities of $3.5 million, leaving $22.8 million of shareholders’ equity largely composed of goodwill and unmonetised trademarks. Research and development expense was $2.6 million in the quarter, while the company reported diluted loss per share of $0.26 on 19.5 million diluted shares. Capital expenditures were zero, and the firm’s operating leases cover headquarters in New York, lab space in Birmingham, Alabama, and a manufacturing service agreement with a third party.

The company’s prospectus filings (S-3/A of 18 May 2026 and 424B5 of 1 June 2026) are heavy on trademarks and light on approvals, restating that the FDA has in the past required boxed warnings on approved CAR-T products, a regulatory precedent the company cannot ignore. The Schedule 13D/A filed 29 May 2026 shows a 13.8% beneficial owner, while accompanying Form 4s show insiders selling shares at prices above current quotes. The company’s shelf registration remains unused while cash continues to leave the building. The gap between the polished platform story and the balance sheet remains the only asset that is undeniably real.

For context on the filing trail, the company’s SEC EDGAR index lists every submission since inception, including the most recent 8-K of 1 June 2026 and the 10-Q of 7 May 2026, which together form the backbone of the current disclosure set. The company’s XBRL company facts API confirms the same financial line items but adds no new product data. The product page on in8bio.com repeats the chemotherapy-plus-immunotherapy claim and displays a cancer-cell image, neither of which constitute regulatory approval or revenue.

The company’s official SEC filings can be browsed via the SEC EDGAR index at https://www.sec.gov/edgar/browse/?CIK=1740279, while the latest 10-Q is available directly at https://www.sec.gov/Archives/edgar/data/1740279/000119312526212135/inab-20260331.htm. The company’s XBRL company facts endpoint is at https://data.sec.gov/api/xbrl/companyfacts/CIK0001740279.json, and the submissions JSON is at https://data.sec.gov/submissions/CIK0001740279.json.